(TCL-B) Transcontinental - Ratings and Ratios
Flexible Packaging, Printing Solutions, Media Publishing
TCL-B EPS (Earnings per Share)
TCL-B Revenue
Description: TCL-B Transcontinental
Transcontinental Inc. (TO:TCL-B) is a diversified company operating in the flexible packaging, retail services, printing, and media sectors across multiple regions, including Canada, the United States, Latin America, the UK, and internationally. Its Packaging segment is a significant player, providing a wide range of packaging solutions, including flexible plastic packaging and advanced coatings, serving various markets such as dairy, coffee, and medical.
With a presence in multiple industries, Transcontinentals revenue streams are somewhat diversified, potentially reducing dependence on a single market. Key Performance Indicators (KPIs) to monitor include revenue growth, EBITDA margins, and return on capital employed (ROCE). The companys ability to maintain profitability in its Packaging segment, amidst fluctuations in raw material prices and demand, will be crucial. Its Retail Services and Printing segments performance in the face of digitalization and changing consumer behavior is also noteworthy.
From a financial perspective, Transcontinentals market capitalization stands at approximately CAD 1.77 billion, with a forward P/E ratio of 7.93, indicating relatively attractive valuation. The companys Return on Equity (RoE) of 9.49% suggests a decent return for shareholders. To further assess its financial health, metrics such as debt-to-equity ratio, interest coverage, and cash flow generation should be examined. A debt-to-equity ratio below 1 and an interest coverage ratio above 3 would be indicative of a stable financial position.
Investors should also focus on the companys ability to generate cash from operations and its capital expenditure requirements to maintain or expand its operations. A strong cash flow generation and a reasonable capital expenditure as a percentage of revenue (capex/revenue) would be positive indicators. Monitoring these KPIs will provide insights into Transcontinentals operational efficiency, financial health, and potential for future growth.
Additional Sources for TCL-B Stock
TCL-B Stock Overview
Market Cap in USD | 1,268m |
Sector | Consumer Cyclical |
Industry | Packaging & Containers |
GiC Sub-Industry | Paper & Plastic Packaging Products & Materials |
IPO / Inception |
TCL-B Stock Ratings
Growth Rating | 46.7 |
Fundamental | 42.0 |
Dividend Rating | 65.6 |
Rel. Strength | 33.8 |
Analysts | - |
Fair Price Momentum | 22.89 CAD |
Fair Price DCF | 629.89 CAD |
TCL-B Dividends
Dividend Yield 12m | 10.94% |
Yield on Cost 5y | 17.99% |
Annual Growth 5y | 0.44% |
Payout Consistency | 63.7% |
Payout Ratio | 89.9% |
TCL-B Growth Ratios
Growth Correlation 3m | 89.2% |
Growth Correlation 12m | 96.5% |
Growth Correlation 5y | 12.2% |
CAGR 5y | 33.87% |
CAGR/Max DD 5y | 0.62 |
Sharpe Ratio 12m | 0.11 |
Alpha | 58.46 |
Beta | 0.485 |
Volatility | 44.08% |
Current Volume | 0k |
Average Volume 20d | 0.1k |
Stop Loss | 20.1 (-2.9%) |
As of July 16, 2025, the stock is trading at CAD 20.70 with a total of 0 shares traded.
Over the past week, the price has changed by -0.48%, over one month by +1.41%, over three months by +18.26% and over the past year by +51.65%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Transcontinental (TO:TCL-B) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 42.04 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TCL-B is around 22.89 CAD . This means that TCL-B is currently undervalued and has a potential upside of +10.58% (Margin of Safety).
Transcontinental has no consensus analysts rating.
According to our own proprietary Forecast Model, TCL-B Transcontinental will be worth about 25 in July 2026. The stock is currently trading at 20.70. This means that the stock has a potential upside of +20.63%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 25 | 20.6% |